52
Regulatory Strategies: ATCase & Haemoglobin

Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Embed Size (px)

Citation preview

Page 1: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Regulatory Strategies: ATCase & Haemoglobin

Page 2: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway

Carbamoyl phosphate + aspartate N-carbamoylaspartate + Pi

Page 3: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Aspartate transcarbamolase

• Catalyses the first step (the committed step) in the biosynthesis of pyrimidines (thiamine and cytosine), bases that are components of nucleic acids

Page 4: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Condensation of aspartate and carbomyl phosphate to form N-Carbamoylaspartate

Page 5: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

• How is the enzyme regulated to generate precisely the amount of CTP needed by the cell?

Page 6: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

CTP inhibits ATCase, despite having little structural similarity to reactants or products

Page 7: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

ATCase Consists of Separate Catalytic and Regulatory Subunits

• Can be separated into regulatory and catalytic subunits by treatment with p-hydroxy-mercuribenzoate, which reacts with sulfhydryl groups

Page 8: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

2c3 + 3r2 c6r6

Ultracentrifugation Activity

PCMBS treated

ACTaseNative ACTase11.6S

2.8S 5.8S

Mercurial dissociate ATCase into two subunits

Page 9: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Subunit characteristics

• Regulatory subunit (r2)– Two chains (17kd each)– Binds CTP– No enzyme activity

• Catalytic subunit (c3)– Three chains– Retains enzyme activity– No response to CTP

Page 10: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Cysteine binds Zn – PCMBS displaces Zn and destabilizes the domain

Structure of ATCase

Page 11: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Potent competitiveinhibitor

Carbamoyl phosphate

Aspartate

Use of PALA to locate active site

Page 12: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Active site of ATCase

Page 13: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

The T-to-R state transition

Each catalytic trimer has 3 substrate binding sites

Enzyme has two quaternary forms.

Page 14: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

CTP stabilises the T state

• T state when CTP bound

• Binding site for CTP

in each regulatory domain

• Binds 50Å from active site– allosteric

Page 15: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

R and T state are in equilibrium

Mechanism for CTP inhibition

Page 16: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

ATCase displays sigmoidal kinetics

T>R

R>T

Cooperativity

Page 17: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Why does ATCase display sigmoidal kinetics

• The importance of the changes in quaternary structure in determining the sigmoidal curve is illustrated by studies on the isolated catalytic trimer, freed by p-hydroxymercuribenzoate treatment.

• The catalytic subunit shows Michaelis-Menten kinetics with kinetic parameters indistinguishable from those deduced for the R-state.

• The term tense is apt – the regulatory dimers hold the two catalytic trimers close so key loops collide & interfere with the conformational adjustments necessary for high affinity binding & catalysis.

Page 18: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Basis for the sigmoidal curve(mixture of two Michaelis Menten enzymes)

High KM

Low KM

Page 19: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Allosteric regulators modulatethe T-to-R equilibrium

Page 20: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

CTP is an allosteric inhibitor

T>R

Page 21: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

ATP is an allosteric activator

High purine

mRNA synthesis ↑

R>T

Page 22: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Haemoglobin

Page 23: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate
Page 24: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Myoglobin

• Myoglobin is a single polypeptide, hemoglobin has four polypeptide chains.

• Haemoglobin is a much more efficient oxygen-carrying protein. Why?

Page 25: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Myoglobin and Haemoglobin bind oxygen at iron atoms in

heme

1 2

3 4

Fe2+

Page 26: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Proximal histidine

Sixth Co-ordination site

Oxygen binding changes the position of the iron ion

Fifth Co-ordination site

Page 27: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Myoglobin – stabilising bound oxygen

Page 28: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Why is haemoglobin more efficient at binding oxygen?

Page 29: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

11 and 22 dimers

Quaternary structure of deoxyhemoglobin - HbA

Page 30: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Oxygen binding to myoglobin

Simple equilibrium.

Page 31: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Haemoglobin as an allosteric protein

• Haemoglobin consists of 2 and 2 chains

• Each chain has an oxygen binding site, therefore haemoglobin can bind 4 molecules of oxygen in total

• The oxygen-binding characteristics of haemoglobin show it to be allosteric

Page 32: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Oxygen binding to haemoglobin in rbc

Cooperativity

Page 33: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Cooperative unloading of oxygen enhances oxygen delivery

Page 34: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Haemoglobin

• Two principal models have been developed to explain how allosteric interactions give rise to sigmoidal binding curves

• The concerted model

• The sequential model

Page 35: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Concerted model

• Oxygen can bind to either conformation, but as the number of sites with oxygen bound increases, so the equilibrium becomes biased towards one conformation (in the case of increasing oxygen bound, the R conformation)

Page 36: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Concerted model

• Developed by Jacques Monod, Jeffries Wyman and Jeanne-Pierre Changeaux in 1965

• In this model all the polypeptide chains must be in an equilibrium that enables two possible conformations to exist

Page 37: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Concerted model

• The concerted model assumes:1. The protein interconverts between the two

conformation T and R but all subunits must be in the same conformation

2. Ligands bind with low affinity to the T state and high affinity to the R state

3. Binding of each ligand increases the probability that all subunits in that protein molecule will be in the R state

Page 38: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Sequential model

• Assumes1. Each polypeptide chain can only adopt one of

two conformations T and R.2. Binding of ligand switches the conformation of

only the subunit bound.3. Conformational change in this subunit alters the

binding affinity of a neighbouring subunit i.e. a T subunit in a TR pair has higher affinity that in a TT pair because the TR subunit interface is different from the TT subunit interface.

Page 39: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Sequential model

• Devised by Dan Koshland in the 1950s

• Substrate binds to one site and causes the polypeptide to change conformation

• Substrate binding to the first site affects the binding of a second substrate to an adjoining site

• And so on for other binding sites …

Page 40: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

How does oxygen binding induce change from T to R state

Page 41: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Quaternary structural changes on oxygen binding (T R)

Rotation of 11 wrt 22 dimers

Page 42: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Conformational change in haemoglobin

T → R

Page 43: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

The role of 2,3 bisphosphoglycerate in red blood

cells

Page 44: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Haemoglobin must remain in T state in absence of oxygen

T – state is extremelyunstable

Page 45: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

2,3-BPG (an allosteric effector) binds & stabilizes the T state (released in R state)

Page 46: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Fetal haemoglobin doesn’t bind 2,3-BPG so well so has higher oxygen affinity

Page 47: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Bohr effect (protons are also allosteric effectors)

T-state stabilized by salt bridges

Thus oxygen is released

Salt bridges

Page 48: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Carbonic anhydrase

Also … CO2 forms carbamate (R-NH-CO2) with N-ter – at interface between αβ dimers favours release of O2 by favouring the T state

Page 49: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Carbon dioxide promotes the release of oxygen

Page 50: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Sickle cell anaemia

Page 51: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

deoxygenated

Β chains

Β chain mutation

Page 52: Regulatory Strategies: ATCase & Haemoglobin. Aspartate transcarbamolase is allosterically inhibited by the end product of its pathway Carbamoyl phosphate

Plasmodium falciparum

Why is HbS so prevalent in Africa

• Sickle cell trait (one allele mutation) resistant to malaria